Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight and obese individuals: the PROGRESS Trial</title><author><name sortKey="Czernichow, Sebastien" sort="Czernichow, Sebastien" uniqKey="Czernichow S" first="Sébastien" last="Czernichow">Sébastien Czernichow</name><affiliation><nlm:aff id="A1">George Institute for International Health, University of Sydney, Sydney, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Department of Public Health, Avicenne Hospital; University of Paris 13, Bobigny, France</nlm:aff></affiliation></author><author><name sortKey="Ninomiya, Toshiharu" sort="Ninomiya, Toshiharu" uniqKey="Ninomiya T" first="Toshiharu" last="Ninomiya">Toshiharu Ninomiya</name><affiliation><nlm:aff id="A1">George Institute for International Health, University of Sydney, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Huxley, Rachel" sort="Huxley, Rachel" uniqKey="Huxley R" first="Rachel" last="Huxley">Rachel Huxley</name><affiliation><nlm:aff id="A1">George Institute for International Health, University of Sydney, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Kengne, Andre Pascal" sort="Kengne, Andre Pascal" uniqKey="Kengne A" first="André-Pascal" last="Kengne">André-Pascal Kengne</name><affiliation><nlm:aff id="A1">George Institute for International Health, University of Sydney, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Batty, G David" sort="Batty, G David" uniqKey="Batty G" first="G David" last="Batty">G David Batty</name><affiliation><nlm:aff id="A1">George Institute for International Health, University of Sydney, Sydney, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="A3">Medical Research Council, Social & Public Health Sciences Unit, Glasgow, UK</nlm:aff></affiliation></author><author><name sortKey="Grobbee, Diederick E" sort="Grobbee, Diederick E" uniqKey="Grobbee D" first="Diederick E." last="Grobbee">Diederick E. Grobbee</name><affiliation><nlm:aff id="A4">Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands</nlm:aff></affiliation></author><author><name sortKey="Woodward, Mark" sort="Woodward, Mark" uniqKey="Woodward M" first="Mark" last="Woodward">Mark Woodward</name><affiliation><nlm:aff id="A1">George Institute for International Health, University of Sydney, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Neal, Bruce" sort="Neal, Bruce" uniqKey="Neal B" first="Bruce" last="Neal">Bruce Neal</name><affiliation><nlm:aff id="A1">George Institute for International Health, University of Sydney, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Chalmers, John" sort="Chalmers, John" uniqKey="Chalmers J" first="John" last="Chalmers">John Chalmers</name><affiliation><nlm:aff id="A1">George Institute for International Health, University of Sydney, Sydney, Australia</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">20212271</idno><idno type="pmc">4170774</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170774</idno><idno type="RBID">PMC:4170774</idno><idno type="doi">10.1161/HYPERTENSIONAHA.109.140624</idno><date when="2010">2010</date><idno type="wicri:Area/Pmc/Corpus">001F83</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001F83</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight and obese individuals: the PROGRESS Trial</title><author><name sortKey="Czernichow, Sebastien" sort="Czernichow, Sebastien" uniqKey="Czernichow S" first="Sébastien" last="Czernichow">Sébastien Czernichow</name><affiliation><nlm:aff id="A1">George Institute for International Health, University of Sydney, Sydney, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="A2">Department of Public Health, Avicenne Hospital; University of Paris 13, Bobigny, France</nlm:aff></affiliation></author><author><name sortKey="Ninomiya, Toshiharu" sort="Ninomiya, Toshiharu" uniqKey="Ninomiya T" first="Toshiharu" last="Ninomiya">Toshiharu Ninomiya</name><affiliation><nlm:aff id="A1">George Institute for International Health, University of Sydney, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Huxley, Rachel" sort="Huxley, Rachel" uniqKey="Huxley R" first="Rachel" last="Huxley">Rachel Huxley</name><affiliation><nlm:aff id="A1">George Institute for International Health, University of Sydney, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Kengne, Andre Pascal" sort="Kengne, Andre Pascal" uniqKey="Kengne A" first="André-Pascal" last="Kengne">André-Pascal Kengne</name><affiliation><nlm:aff id="A1">George Institute for International Health, University of Sydney, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Batty, G David" sort="Batty, G David" uniqKey="Batty G" first="G David" last="Batty">G David Batty</name><affiliation><nlm:aff id="A1">George Institute for International Health, University of Sydney, Sydney, Australia</nlm:aff></affiliation><affiliation><nlm:aff id="A3">Medical Research Council, Social & Public Health Sciences Unit, Glasgow, UK</nlm:aff></affiliation></author><author><name sortKey="Grobbee, Diederick E" sort="Grobbee, Diederick E" uniqKey="Grobbee D" first="Diederick E." last="Grobbee">Diederick E. Grobbee</name><affiliation><nlm:aff id="A4">Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands</nlm:aff></affiliation></author><author><name sortKey="Woodward, Mark" sort="Woodward, Mark" uniqKey="Woodward M" first="Mark" last="Woodward">Mark Woodward</name><affiliation><nlm:aff id="A1">George Institute for International Health, University of Sydney, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Neal, Bruce" sort="Neal, Bruce" uniqKey="Neal B" first="Bruce" last="Neal">Bruce Neal</name><affiliation><nlm:aff id="A1">George Institute for International Health, University of Sydney, Sydney, Australia</nlm:aff></affiliation></author><author><name sortKey="Chalmers, John" sort="Chalmers, John" uniqKey="Chalmers J" first="John" last="Chalmers">John Chalmers</name><affiliation><nlm:aff id="A1">George Institute for International Health, University of Sydney, Sydney, Australia</nlm:aff></affiliation></author></analytic><series><title level="j">Hypertension</title><idno type="ISSN">0194-911X</idno><idno type="eISSN">1524-4563</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">There is considerable uncertainty regarding the efficacy of blood pressure-lowering therapy in reducing cardiovascular risk in obese people. In this report we examine the effects of blood pressure lowering according to baseline body mass index (kg/m<sup>2</sup>) in the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). A total of 6105 participants with cerebrovascular disease were randomized to perindopril-based blood pressure-lowering therapy or placebo. The overall mean difference in systolic/diastolic blood pressure between participants assigned active therapy or placebo was 9/4 (SE, 0.5/0.3) mmHg, with no difference by body mass index quarters: < 23.1, 23.1-25.3, 25.4-27.8 and ≥ 27.9 kg/m<sup>2</sup>. A consistent treatment benefit was demonstrated for protection against major vascular events across quarters with the following hazard ratios (95% confidence intervals): 0.80 (0.62-1.02), 0.78 (0.61-1.01), 0.67 (0.53-0.86), 0.69 (0.54-0.88) and 0.74 (0.66-0.84) (p for heterogeneity = 0.16). Similar results were apparent for stroke and stroke subtypes (all p for heterogeneity ≥ 0.07) or with the standard definitions of overweight and obesity (< 25, 25 to 29 and ≥ 30 kg/m) (all p for heterogeneity ≥ 0.28). The absolute effects of treatment were, however, more than twice that in the highest compared with the lowest body mass index quartile. Across increasing quarters of body mass index over five years, active therapy prevented one major vascular event among every 28, 23, 13 and 13 patients treated. In conclusion, blood pressure-lowering therapy produced comparable risk reductions in vascular disease across the whole range of body mass index in participants with a history of stroke. However, the greater baseline level of cardiovascular risk in those with higher body mass index meant that these patients obtained the greatest benefit.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">7906255</journal-id><journal-id journal-id-type="pubmed-jr-id">4217</journal-id><journal-id journal-id-type="nlm-ta">Hypertension</journal-id><journal-id journal-id-type="iso-abbrev">Hypertension</journal-id><journal-title-group><journal-title>Hypertension</journal-title></journal-title-group><issn pub-type="ppub">0194-911X</issn><issn pub-type="epub">1524-4563</issn></journal-meta><article-meta><article-id pub-id-type="pmid">20212271</article-id><article-id pub-id-type="pmc">4170774</article-id><article-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.109.140624</article-id><article-id pub-id-type="manuscript">EMS60289</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight and obese individuals: the PROGRESS Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Czernichow</surname><given-names>Sébastien</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ninomiya</surname><given-names>Toshiharu</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Huxley</surname><given-names>Rachel</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kengne</surname><given-names>André-Pascal</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Batty</surname><given-names>G David</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Grobbee</surname><given-names>Diederick E.</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Woodward</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Neal</surname><given-names>Bruce</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chalmers</surname><given-names>John</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>George Institute for International Health, University of Sydney, Sydney, Australia</aff><aff id="A2"><label>2</label>Department of Public Health, Avicenne Hospital; University of Paris 13, Bobigny, France</aff><aff id="A3"><label>3</label>Medical Research Council, Social & Public Health Sciences Unit, Glasgow, UK</aff><aff id="A4"><label>4</label>Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands</aff><author-notes><corresp id="CR1"><bold>Corresponding author for reprint and request:</bold> Assoc/Prof. Sébastien Czernichow Unité de Recherche en Epidémiologie Nutritionnelle Faculté de médecine SMBH. 74, rue Marcel Cachin, 93017 Bobigny, France Tel: +33 1 48 38 89 32, Fax: +33 1 48 38 89 31 <email>czernichow@uren.smbh.univ-paris13.fr</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>4</day><month>9</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>08</day><month>3</month><year>2010</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2010</year></pub-date><pub-date pub-type="pmc-release"><day>22</day><month>9</month><year>2014</year></pub-date><volume>55</volume><issue>5</issue><fpage>1193</fpage><lpage>1198</lpage><pmc-comment>elocation-id from pubmed: 10.1161/HYPERTENSIONAHA.109.140624</pmc-comment>
<abstract><p id="P1">There is considerable uncertainty regarding the efficacy of blood pressure-lowering therapy in reducing cardiovascular risk in obese people. In this report we examine the effects of blood pressure lowering according to baseline body mass index (kg/m<sup>2</sup>) in the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). A total of 6105 participants with cerebrovascular disease were randomized to perindopril-based blood pressure-lowering therapy or placebo. The overall mean difference in systolic/diastolic blood pressure between participants assigned active therapy or placebo was 9/4 (SE, 0.5/0.3) mmHg, with no difference by body mass index quarters: < 23.1, 23.1-25.3, 25.4-27.8 and ≥ 27.9 kg/m<sup>2</sup>. A consistent treatment benefit was demonstrated for protection against major vascular events across quarters with the following hazard ratios (95% confidence intervals): 0.80 (0.62-1.02), 0.78 (0.61-1.01), 0.67 (0.53-0.86), 0.69 (0.54-0.88) and 0.74 (0.66-0.84) (p for heterogeneity = 0.16). Similar results were apparent for stroke and stroke subtypes (all p for heterogeneity ≥ 0.07) or with the standard definitions of overweight and obesity (< 25, 25 to 29 and ≥ 30 kg/m) (all p for heterogeneity ≥ 0.28). The absolute effects of treatment were, however, more than twice that in the highest compared with the lowest body mass index quartile. Across increasing quarters of body mass index over five years, active therapy prevented one major vascular event among every 28, 23, 13 and 13 patients treated. In conclusion, blood pressure-lowering therapy produced comparable risk reductions in vascular disease across the whole range of body mass index in participants with a history of stroke. However, the greater baseline level of cardiovascular risk in those with higher body mass index meant that these patients obtained the greatest benefit.</p></abstract><kwd-group><kwd>obesity</kwd><kwd>blood pressure</kwd><kwd>perindopril</kwd><kwd>cardiovascular disease</kwd><kwd>stroke</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F83 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001F83 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.33. |  |